Renkangya (Shenzhen) Biomedical Technology Co., Ltd.

Primary objective: To explore the efficacy and safety of GNPs for injection in patients with acute decompensated heart failure. Secondary objectives: (1) To explore the pharmacokinetic characteristics of GNPs for injection in patients with acute decompensated heart failure; (2) To explore the immunogenicity characteristics of GNPs for injection in patients with acute decompensated heart failure;

Primary objective: To evaluate the safety and tolerability of GNPs after single-ascending doses in healthy adult Chinese subjects and compare with placebo. Secondary objectives: (1) To evaluate the pharmacokinetic parameters of GNPs after single-ascending doses in healthy subjects. (2) To evaluate the pharmacodynamic characteristics of GNPs after single-ascending doses in healthy subjects. (3) To evaluate the immunogenicity characteristics of GNPs after single-ascending doses in healthy subjects. Exploratory objective: To explore the dose-response relationship between drug dose exposure and drug effect using model guidance.